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Cooperative interactions between growth factor signaling pathways are important elements in carcinoma
progression. A model system combining transforming growth factor-b1 (TGF-b1) and EGF was developed to
investigate mechanisms underlying induced epithelial-to-mesenchymal transition (EMT) in ras-transformed
human (HaCaT II-4) keratinocytes. Dual stimulation with TGF-b1þ EGF resulted in keratinocyte ‘‘plasticity’’ and
pronounced colony dispersal. The most highly expressed transcript, identified by mRNA profiling, encoded
plasminogen activator inhibitor-1 (PAI-1; SERPINE1). PAI-1 negatively regulates plasmin-dependent matrix
degradation, preserving a stromal scaffold permissive for keratinocyte motility. Mitogen-activated extracellular
kinase (MEK)/extracellular signal-regulated kinase (ERK) and p38 signaling were required for maximal
PAI-1 upregulation and TGF-b1þ EGF-stimulated cell locomotion, as pharmacologic disruption of MEK/p38
activity ablated both responses. Moreover, PAI-1 knockdown alone effectively inhibited TGF-b1þ EGF-
dependent cell scattering, indicating a functional role for this SERPIN in the dual-growth factor model of
induced motility. Moreover, EGFR signaling blockade or EGFR knockdown attenuated TGF-b1-induced
PAI-1 expression, implicating EGFR transactivation in TGF-b1-stimulated PAI-1 expression, and reduced
colony dispersal in TGF-b1þ EGF-treated cultures. Identification of such cooperative signaling networks
and their effect on specific invasion-promoting target genes, such as PAI-1, may lead to the development of
pathway-specific therapeutics that affect late-stage events in human tumor progression.
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INTRODUCTION
The emergence of highly aggressive squamous cell carcino-
mas (SCCs) in mouse models is causally linked to p53
mutation, Ha-ras activation, and increased expression of
transforming growth factor-b1 (TGF-b1) (Portella et al., 1998;
Yuspa, 1998; Akhurst and Balmain, 1999; Boukamp, 2005;
Smoller, 2006). Although typically antiproliferative for
normal and early-transformed epithelial cells, TGF-b1 has
protumorigenic effects on late-stage murine malignancies
due, at least in part, to ras-dependent antagonism of growth
inhibition and apoptosis programs (Cui et al., 1996; Go et al.,
1999; Kretzschmar et al., 1999; Derynck et al., 2001; Han
et al., 2005; Kim et al., 2005). Recent findings suggest a
mechanism for such signaling dichotomy. TGF-b-dependent
COOH-terminal Smad3 phosphorylation initiates growth
restriction in normal cells, whereas oncogenic Ha-ras
activates c-Jun N-terminal kinase-mediated Smad2/3 linker
region phosphorylation, resulting in the upregulation of
several important tumor progression genes (Sekimoto et al.,
2007). This is particularly relevant to TGF-b1-initiated
‘‘plasticity’’ in susceptible epithelial cells (usually referred
to as epithelial-to-mesenchymal transition (EMT)), a response
linked to ras signaling (Oft et al., 1996, 2002; Tian et al.,
2007; Samarakoon et al., 2008; Joo et al., 2008; Uttamsingh
et al., 2008). Indeed, acquisition of mesenchymal-like traits
with creation of a morphologically restructured, motile
phenotype (see, e.g., Heldin et al., 2009; Thiery and
Sleeman, 2006) is thought to facilitate development of
invasive carcinomas (Cui et al., 1996; Portella et al., 1998;
Zavadil et al., 2001; Zavadil and Bottinger, 2005; Peinado
et al., 2007).
Data mining of the repertoire of TGF-b1-regulated
‘‘plasticity’’ genes in human malignant keratinocytes has
produced some remarkable consistencies. The most promi-
nently induced transcript encodes plasminogen activator
inhibitor type-1 (PAI-1; SERPINE1), the major physiologic
regulator of the pericellular plasmin-generating cascade
(Akiyoshi et al., 2001; Zavadil et al., 2001; Sekimoto et al.,
2007). PAI-1 is highly induced in epithelial cells undergoing
an EMT-like conversion upon expression of the E-cadherin
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transcriptional repressors Snail, Slug, or E47 (Moreno-Bueno
et al., 2006). In incipient epidermal SCC, PAI-1 often
localizes in tumor cells and myofibroblasts at the invasive
front (Wilkins-Port et al., 2007), implying involvement as a
positive modulator of cellular invasive potential (Christensen
et al., 1996; Offersen et al., 2003; Illemann et al., 2004).
Elevated PAI-1 tumor levels, in fact, signal a poor prognosis
and reduced disease-free survival in patients with breast,
lung, ovarian, gastric, and oral malignancies (Pedersen et al.,
1994; Andreasen et al., 1997; Hersze`nyi et al., 1999; Chen
et al., 2004; Vairaktaris et al., 2005; Lindberg et al., 2006;
Sakakibara et al., 2006; Sternlicht et al., 2006). Moreover,
in vivo modeling in knockout mice identified PAI-1 as an
essential element in cutaneous cancer invasion and the
associated angiogenic response (see, e.g., Bajou et al., 1998;
Bajou et al., 2001). PAI-1 likely maintains an angiogenic
‘‘scaffold,’’ stabilizes nascent capillaries, and regulates tumor
cell invasion through focalized control of the proteolytic
environment (Bacharach et al., 1998; Bajou et al., 2001,
2004, 2008; Davis et al., 2001; Maillard et al., 2005) as well
as by competitive interactions with matrix vitronectin (for
integrin binding) and cell surface LDL receptor-related
protein (Degryse et al., 2004).
Identifying mechanisms underlying TGF-b signaling that
affect expression of tumor progression genes is complicated
and involves the engagement of both canonical and
noncanonical pathways downstream of the activated TGF-b
receptors (see, e.g., Zhang, 2009). In several cell types,
including human (HaCaT) keratinocytes, for example, EGFR
transactivation upon TGF-b1 stimulation contributes to signal
bifurcation (Kim and Joo, 2002; Joo et al., 2008; Samarakoon
et al., 2008). This has significant pathophysiologic ramifica-
tions. During cutaneous SCC development, for example,
elevated TGF-b1 levels in the tumor microenvironment are
accompanied by EGFR amplification and/or dysregulated
signaling (Rho et al., 1994; O-Charoenrat et al., 2000, 2002).
Therefore, to more specifically define inductive controls and
potential functions for plasticity-associated PAI-1 expression
in human cutaneous SCC, a physiologically relevant model
system was established. Transformed human keratinocytes
(HaCaT II-4 cells), which possess UV signature mutations in
both p53 alleles (C-T and CC-TT at codons 179 and 281/
282) (Lehman et al., 1993; Elmageed et al., 2009) as well as
an activated Ha-rasval12 gene, were stimulated with TGF-
b1þ EGF to closely mimic pathway co-activation typical of
late-stage malignancies. Simultaneous addition of TGF-
b1þ EGF (when compared with either growth factor alone)
was required to develop the full plastic response involving
E-cadherin downregulation, induction of mesenchymal
markers (vimentin, a-smooth muscle actin, and N-cadherin),
increased cell motility (i.e., colony ‘‘scattering’’), and
maximal PAI-1 expression. Small interfering (siRNA)-directed
PAI-1 knockdown effectively inhibited dual-growth factor-
stimulated colony dispersal, supporting a role for this SERPIN
in tumor cell migration. Moreover, pharmacologic blockade
of EGFR signaling (with AG1478) and shRNA-mediated EGFR
reduction effectively inhibited both TGF-b1-induced PAI-1
expression and cell scattering. A model is presented in which
TGF-b1 activates two distinct but cooperative downstream
pathways consistent with the known relationship between
ras-mitogen-activated protein (MAP) kinase signaling and
TGF-b1-initiated EMT.
RESULTS
TGF-b1þ EGF co-stimulation elicits a plastic response in HaCaT
II-4 cells
To assess the consequences of TGF-bþ EGF signaling, p53
mutant, ras-transformed human (HaCaT II-4) keratinocytes,
grown as small colonies, were serum starved for 3 days to
initiate a G0 arrest (growth kinetics detailed in Qi et al., 2006,
2008) before stimulation with TGF-b1 (1 ngml–1) and EGF
(10 ngml–1) (Figure 1a). Within 48 hours, the discrete colonies
of normally sedentary, cuboidal-shaped, and tightly juxta-
posed keratinocytes underwent pronounced morphological
and motile changes (Figure 1b and c),a phenotypic conver-
sion accompanied by E-cadherin downregulation and the
acquisition of prominent but heterogeneously distributed
N-cadherin immunoreactivity (Figure 1d). Colony dispersal
(Figure 1b and c) was coincident with de novo expression of
a-smooth muscle actin and vimentin (with construction of a
vimentin-rich intermediate filament network; Figure 1d), both
established markers of epithelial cell plasticity (reviewed in
Moustakas and Heldin, 2007). The synthesis of vimentin
similarly characterizes the invading epithelial cohort at the
periphery of HaCaT II-4 transplants in immunocompromized
mice (Tomakidi et al., 2003).
TGF-b1 when used alone promoted a more flattened
morphology with loss of cell–cell contact and induced
N-cadherin expression (Figure 2a and b), whereas EGF
clearly initiated a proliferative response (Figure 2a and c).
Optimal colony dispersal required both growth factors,
although the expression of certain EMT ‘‘markers’’ (such as
N-cadherin) was TGF-b1 dependent (Figure 2a and b).
Moreover, TGF-b1þ EGF-stimulated keratinocyte scattering
was proliferation independent; TGF-b1 retained its growth-
suppressive effects even in the presence of mitogenic levels of
EGF, as determined by quantitative assessments of the cell
cycle markers cyclin A and Ki-67 (Figure 2c). This is consistent
with recent findings that TGF-b1 suppresses EGF-induced
S-phase entry in HaCaT II-4 cells (Wilkins-Port et al., 2009)
and indicates, moreover, that TGF-b1þ EGF-stimulated
plasticity does not require concomitant cell proliferation.
Furthermore, deprivation of fetal bovine serum for 3 days did
not initiate an apoptotic response or permanent growth arrest,
as quiescent HaCaT II-4 cells re-entered the proliferative cycle
upon reintroduction of serum (not shown).
Colony dispersal in TGF-b1þ EGF-stimulated HaCaT II-4
keratinocytes involves p38, MEK/ERK, and upstream EGFR
signaling
As cell scattering is an in vitro correlate of invasive
behavior, it was important to define signaling pathways
underlying TGF-b1þ EGF-stimulated motility. p38 and
mitogen-activated extracellular kinase (MEK)/extracellular
signal-regulated kinase (ERK) phosphorylation both increased
within 15minutes of TGF-b1þ EGF addition, although the
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duration of response differed (Figure 3a). Although phospho-
p38 returned to approximately basal levels by 12 hours,
ERK1/2 remained phosphorylated throughout the entire
course of growth factor treatment (48 hours), paralleling the
complete emergence of plasticity-related markers and full
colony dispersal. Preincubation with the MEK inhibitor
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Figure 1. TGF-b1þ EGF induce a plastic response in HaCaT II-4 cells. (a) A model system was devised in which small colonies of HaCaT II-4 cells
seeded on tissue culture plastic were serum starved, followed by stimulation with a combination of transforming growth factor-b1 (TGF-b1; 1 ngml–1) and
EGF (10 ngml–1). (b, c) Acquisition of a spindle-shaped, highly migratory phenotype resulted in marked colony dispersal within 24–48 hours. Data plotted in
c is the mean±SD of ImageJ measurements on 10 arbitrarily selected colonies; ***Pp0.001. The pixel area of unscattered and dispersed colonies was measured
using NIH ImageJ software for cultures stimulated with TGF-b1þ EGF for 48 hours (e.g., as in b) after a 3-day serum-free incubation or maintained under control
(quiescence) conditions for a comparable period. (d) Cell scattering was accompanied by the loss of E-cadherin (green) immunostaining at
cell–cell junctions (48 hours), and the gain of several mesenchymal markers, such as N-cadherin (48 hours; although heterogeneously), a-smooth muscle actin
(a-SMA, 24 hours), and vimentin (72 hours) (all red). Scale bars are as follows: in b¼100 mm; in d (E-cadherin) ¼10 mm, (N-Cadherin, a-SMA, and
Vimentin) ¼20 mm. Nuclei are visualized with 4,6-diamidino-2-phenylindole (DAPI); the red counterstain in E-Cadherin panels (d) is Texas red–X phalloidin.
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Figure 2. TGF-b1 and EGF differentially affect HaCaT II-4 phenotype. When used individually for 48 hours, transforming growth factor-b1 (TGF-b1) generated
flat, less closely juxtaposed cells (a) and high-level N-cadherin expression (b). EGF stimulated cell proliferation (a, c) but not N-cadherin synthesis (b). Colony
dispersal in TGF-b1þ EGF-stimulated keratinocyte cultures (a) occurs in the absence of induced proliferation (c). Fetal Bovine Serum (FBS; 10% final
concentration), EGF (10 ngml–1), TGF-b1 (1 ngml–1), or the combination of TGF-b1þ EGF was added to 3-day serum-deprived HaCaT II-4 cells and the fraction
of cyclin A- or Ki-67 positive keratinocytes was assessed using immunocytochemistry 24 hours later (c). FBS (used as a positive control) and EGF stimulation
significantly increased the number of cyclin A- and Ki67-expressing cells. Simultaneous addition of TGF-b1 in the presence of EGF (EGFþ TGF-b1) effectively
attenuated the EGF-induced increase in both cell cycle markers. Data plotted (c) are the meanþ SD of triplicate assessments. Scale bar in a¼ 100mm.
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U0126 significantly attenuated TGF-b1þ EGF-initiated Ha-
CaT II-4 cell motility and retained E-cadherin staining at
cell–cell junctions, as did blockade of p38 kinase activity
with either PD169316 or SB220025 (Figure 3b and c),
coincident with decreased phosphorylation of the phospho-
p38 downstream target HSP27 (Figure 3d). It was established
previously that EGF and TGF-b1 (when used separately)
activated MAP kinase pathways in HaCaT II-4 cells, and this
response is sensitive to the EGFR inhibitor AG1478 (Kutz
et al., 2006; Wilkins-Port et al., 2009). In conformity with
these results, inhibition of EGFR signaling by pretreatment
with AG1478 completely prevented TGF-b1þ EGF-stimu-
lated colony dispersal and the associated E-cadherin loss at
cell–cell contact points (Figure 4a). Collectively, these data
suggest an EGFR-MAP kinase axis in the dual-growth factor
model of induced keratinocyte migration. To verify participa-
tion of the EGFR in the TGF-b1þ EGF-stimulated scattering
response, HaCaT II-4 cells were infected with EGFR short
hairpin RNA lentiviruses to reduce cellular EGFR levels.
Consistent with the pharmacologic approach, targeted EGFR
knockdown (Figure 4b) effectively attenuated colony scatter-
ing after TGF-b1þ EGF addition (Figure 4c).
PAI-1 is a prominent member of the TGF-b1þ EGF-upregulated
gene set and required for colony dispersal
Quantitative reverse transcriptase-PCR (qRT-PCR) array pro-
filing of HaCaT II-4 keratinocytes stimulated with TGF-b1
and/or EGF provided an initial assessment of potential
effectors of TGF-b1þ EGF-induced cell scattering. PAI-1
(SERPINE1), a regulator of keratinocyte migration (see, e.g.,
Providence et al., 2008), was identified as the most
prominently upregulated transcript (Figure 5), an increase
verified by RT-PCR (data not shown) and western blotting
(Figure 6a). Individually, both EGF and TGF-b1 enhanced
PAI-1 mRNA expression (10- and 74-fold, respectively).
However, combining TGF-b1 and EGF resulted in a 170-fold
increase in PAI-1 mRNA and protein levels, suggesting that
induction associated with dual-growth factor treatment was
more than simply additive (Figures 5 and 6a). Moreover,
kinetic analysis indicated that PAI-1 induction was first
evident within 1 hour of TGF-b1þ EGF addition and
sustained for over 24 hours (Figure 6b). Therefore, the
initiation of PAI-1 expression preceded and, over the long
term, correlated temporally with the development of cellular
plasticity and colony dispersal.
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Figure 3. TGF-b1þ EGF-induced colony dispersal requires both p38 and MEK/ERK signaling. (a) Assessments of pERK1/2 and phospho-p38 (pp38) levels
indicated that the mitogen-activated extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) and p38 signaling pathways are activated within
15minutes of transforming growth factor-b1 (TGF-b1) and EGF addition. ERK1/2 phosphorylation was sustained over 48 hours, whereas pp38 returned to basal
levels by 12 hours after stimulation. Protein loading levels were confirmed by immunoblotting for total p38 and ERK2. Preincubation with the MEK inhibitor,
U0126, as well as the p38 inhibitors, PD169316 and SB220025, completely blocked TGF-b1þ EGF-stimulated keratinocyte motility and colony dispersal in
48-hour TGF-b1þ EGF-treated cultures (b), and prevented loss of E-cadherin from cell–cell junctions (c). ImageJ analysis of colony area verified the visual
assessments (not shown) in b. Lack of colony dispersal in cultures pretreated with kinase inhibitors was not due to associated toxicity, as removal of drugs
followed by addition of DMEM/10% fetal bovine serum (FBS) promoted a rapid re-entry into exponential phase growth. Phosphorylation of the pp38 target
protein HSP27 in response to a 1-hour TGF-b1þ EGF stimulation was reduced to near-basal levels by pretreatment (for 0.5 or 1 hour) with PD169316 and
SB220025. The expected pp38 activation in the presence of PD169316 or SB220025 and decreased HSP27 phosphorylation confirmed that these compounds
function in HaCaT II-4 cells to effectively inhibit p38 downstream activity (c). Scale bars in b¼100 mm; in c¼10 mm.
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Similar to requirements for TGF-b1þ EGF-stimulated
colony dispersal (Figure 3b), TGF-b1þ EGF-induced PAI-1
expression was also attenuated by inhibitors of MAP kinase
signaling (Figure 6c) as well as the EGFR inhibitor AG1478
(Figure 6d), suggesting a potential link between PAI-1
expression and cell scattering. Moreover, simultaneous
inhibition of both the MEK/ERK and p38 MAP kinase
pathways completely ablated PAI-1 expression (Figure 6c).
Pretreatment of HaCaT II-4 keratinocytes with AG1478
abolished EGF-dependent PAI-1 induction (as expected),
and also markedly attenuated TGF-b1-stimulated PAI-1
expression (Figure 6d). This latter finding reflects the
increased EGFR activation (phosphorylation) at the Y845 site
and internalization evident in TGF-b1-stimulated HaCaT II-4
cells (Figure 7a and b) and the requirement for EGFR
presence for maintenance of the PAI-1 response (Figure 7c).
Importantly, the synergistic increase in PAI-1 levels in
TGF-b1þ EGF-treated cultures was also significantly reduced
by EGFR inhibition with AG1478 (Figure 6d) as was colony
dispersal (Figure 4a), suggesting an important role for EGFR
signaling in both events. HaCaT II-4 cells with reduced EGFR
levels also had significantly lower levels of PAI-1 after growth
factor treatment, either singularly or in combination (not
shown). These data highlight the TGF-b and EGF receptor
signaling synergies reported previously in other cell types
(Tian et al., 2007; Uttamsingh et al., 2008).
As PAI-1 stimulates directional migration in response to
monolayer scrape injury (Degryse et al., 2004; Providence
et al., 2008), it was important to determine whether PAI-1
also contributed to TGF-b1þ EGF HaCaT II-4 keratinocyte
motility. Pretreatment with a function-blocking (i.e., neutra-
lizing) antibody to PAI-1 significantly reduced the percentage
of scattered colonies in dual-growth factor-treated cultures
(Figure 8a). siRNA-mediated PAI-1 knockdown (Figure 8b)
similarly decreased TGF-b1þ EGF-stimulated colony disper-
sal (Figure 8c), confirming involvement of this SERPIN in at
least several models of induced planar motility (cf., Degryse
et al., 2004; Providence et al., 2008). Finally, the Oris cell
invasion assay confirmed the necessity for PAI-1 in basement
membrane extract barrier penetration. TGF-b1þ EGF signifi-
cantly increased invasion of HaCaT II-4 cells as did
exogenous addition of PAI-1 alone; inhibition of EGFR or
p38/MEK signaling attenuated TGF-b1þ EGF-dependent mi-
gration (Figure 9a). HaCaT II-4 keratinocytes transfected with
a control (CTL) or PAI-1 (PAI) siRNA were subsequently used
in a long-term Oris invasion assay. In this system, PAI-1
knockdown (by approximately 80%; a consequence of the
protracted time course of this evaluation when compared
with the almost complete attenuation of PAI-1 expression in
a shorter time frame context used in the scattering assay
in Figure 8b) reduced both basal invasion as well as
TGF-b1þ EGF-stimulated migration by 50% (Figure 9b
and c). Collectively, these data establish the requirement for
PAI-1 expression for TGF-b1þ EGF-stimulated colony dis-
persal as well as barrier invasion in HaCaT II-4 keratinocytes.
DISCUSSION
Aggressive SCCs often emerge from specific transdifferentia-
tion events that switch normally polarized epithelial cells to a
more ‘‘plastic,’’ invasive phenotype. To define mechanisms
associated with this pathological response in a cutaneous
system, ras-transformed HaCaT II-4 keratinocytes were
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Figure 4. Participation of the EGFR in TGF-b1þ EGF-induced colony scattering. (a) Inhibition of EGFR kinase activity with AG1478 effectively eliminated
transforming growth factor-b1 (TGF-b1) and EGF-stimulated cell scattering (left panels) and retained E-cadherin immunolocalization (right panels) at cell–cell
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stimulated with a combination of TGF-b1þ EGF to recapitu-
late the increase in TGF-b1 expression and amplification/
dysregulation of EGFR signaling frequently observed in
metastatic carcinomas (Rho et al., 1994; Derynck et al.,
2001; Shimizu et al., 2001; Weeks et al., 2001).
The transcriptional profile of TGF-b1þ EGF-treated
HaCaT II-4 keratinocytes was relatively unique compared
with cultures exposed to either growth factor alone, suggest-
ing cooperativity in downstream signaling as a consequence
of TGF-bR/EGFR activation. Although TGF-b1 initiates
EMT-related events in the HaCaT system (Zavadil et al.,
2001), the extent of cell scattering was not as profound as that
associated with the combination of TGF-b1þ EGF. Moreover,
this response was not unique to HaCaT II-4 keratinocytes as a
similar effect of the combined TGF-b1þ EGF treatment was
also evident in SCC-25 oral squamous carcinoma and A431
cells (not shown). In this regard, the expression of several
plasticity markers, moreover, was most apparent with dual-
growth factor stimulation, suggesting that EGF supports, or
augments, development of the plastic phenotype. Indeed,
both EGFR ligand-dependent (i.e., ADAM mediated) and
-independent TGF-bR/EGFR cross-talk has been reported in
several cell systems, including HaCaT keratinocytes (Wang
et al., 2008; Joo et al., 2008), and may contribute specifically
to PAI-1 expression in much the same way as ADAM-17 may
enhance PAI-1 expression in phorbol ester-treated cells (Arts
et al., 1999; Mussoni et al., 2000; Horiuchi et al., 2007).
Cross-talk between TGF-b1 (or HGF) and EGFR results in a
MAP kinase-dependent upregulation of several proteases
(Tian et al., 2007; Zhou et al., 2007; Uttamsingh et al., 2008).
In this system, synergistic increases in matrix metalloprotei-
nases 1 and 9, as well as the serine proteinase inhibitor PAI-1
in response to TGF-b1þ EGF addition, were evident. PAI-1,
which modulates downstream MMP activation and stromal
remodeling (Wilkins-Port et al., 2009), was the most highly
upregulated transcript and causally linked to TGF-b1þ EGF-
induced cell scattering. This study shows for the first time a
fundamental role for PAI-1 in growth factor-induced motility
and transdifferentiation in malignant human keratinocytes.
The p38 and MEK/ERK pathways were both activated upon
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Figure 5. Plasminogen activator inhibitor-1 (PAI-1) is a prominent member of the TGF-b1þ EGF-upregulated gene set. Of the several upregulated and
downregulated transcripts identified by focused microarray analysis at 6 hours after stimulation with TGF-b1þ EGF, the most highly upregulated is PAI-1
(170-fold over control). TGF-b1 and EGF, when used alone, induced a 74-fold and 10-fold increase, respectively. Other genes commonly associated with cancer
progression and metastasis were also upregulated, as well as members of the proteolytic cascade (i.e., several MMPs) and plasminogen activation system
(i.e., uPA and uPAR). Relative expression levels for each gene was normalized to that of GAPDH using the PCR Array Data Analysis Web Portal to calculate
DDCt-based fold-change in transcript abundance. ANGPT1, angiopoietin 1; BRCA1, breast cancer 1, early onset; CDK2, cyclin-dependent kinase 2; CDKN1A,
cyclin-dependent kinase inhibitor 1A (p21, Cip1); IFN-a1, interferon-a1; IFN-b1, interferon-b1, fibroblast; ITGa1, integrin a1; ITGa2, integrin a2; ITGb1,
integrin b1; ITGb3, integrin b3; ITGb5, integrin b5; MMP-1, matrix metallopeptidase 1; MMP-9, matrix metallopeptidase 9; MTA1, metastasis-associated 1;
MTA2, metastasis-associated 1 family, member 2; MTSS1, metastasis suppressor 1; PDGFb, platelet-derived growth factor b polypeptide; PLAU, urokinase
plasminogen activator; PLAUR, urokinase plasminogen activator receptor; SERPINE1, serpin peptidase inhibitor, clade E (plasminogen activator inhibitor-1);
TGF-b1, transforming growth factor-b1; TGF-bR1, transforming growth factor-b receptor 1; THBS1, thrombopsondin 1; TNFRSF10B, tumor necrosis factor
receptor superfamily, member 10b; TNFRSF25, tumor necrosis factor receptor superfamily, member 25; VEGFA, vascular endothelial growth factor A.
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TGF-b1þ EGF stimulation and necessary for maximal induc-
tion of PAI-1, as well as the development of a migratory
phenotype. MAP kinase signaling in other systems also affects
motility-related molecules such as Snail (Grotegut et al.,
2006) and myosin light chain kinase (Klemke et al., 1997).
Although TGF-b1 and EGF are known promoters of MAP
kinase signaling, this study establishes a direct correlation
between TGF-b1þ EGF-dependent MAP kinase pathway
stimulation, PAI-1-dependent HaCaT II-4 cell scattering,
and EMT, consistent with recent studies (Zuo and Chen,
2009). It is apparent that a complicated, cooperative
interaction exists between intracellular events orchestrated
by TGF-b1-activated pathways and the EGFR, which speci-
fically lead to epithelial tumor plasticity. PAI-1 induction in
response to TGF-b1 involves a complex network of signaling
intermediates and requires the activities of the MEK, p21ras,
and pp60csrc in addition to the EGFR (Kutz et al., 2006), with
pp60csrc a critical intermediate in the cascade leading to
MEK signaling, PAI-1 transcription, and subsequent pheno-
typic responses (e.g., Samarakoon et al., 2005; Sato et al.,
2005). The src family kinase inhibitors and dominant-
negative pp60csrc constructs effectively attenuate TGF-b1-
induced PAI-1 expression in HaCaT cells (Kutz et al., 2006),
confirming the generality of src kinase involvement in PAI-1
gene regulation. The effective blockade of TGF-b1-stimulated
ERK1/2 phosphorylation and PAI-1 transcription by inter-
ference with src kinase activity as well as with the EGFR
inhibitor AG1478, and the requirement for MEK/ERK signal-
ing for the full inductive effect of TGF-b1, suggests that
pp60csrc, perhaps through phosphorylation of the Y845 src-
specific EGFR target residue, regulates the EGFR-MEK/ERK-
dependent PAI-1 expression transduction cascade. Although
the role of individual MAP kinases remains to be determined,
ERK activation through TGF-b1/EGFR cross-talk may
involve Sprouty2, which prolongs EGF signaling by titering
EGFR ubiquitination (Ding et al., 2007). Sprouty2 levels
decrease after TGF-b1 stimulation, an effect that could
not be rescued with additional EGF (Ding et al., 2007)
despite the ability of EGF to upregulate Sprouty2 expression
(Ozaki et al., 2001). A similar dominant inhibitory effect was
observed in HaCaT II-4 cells, as EGF stimulation was unable
to overcome the growth-suppressive effects of TGF-b1.
Therefore, the potential contribution of Sprouty2 to TGF-b1/
EGF-dependent events in the present system warrants further
investigation.
The continued definition of specific molecular mechan-
isms underlying control of tumor progression genes is an
essential element in the ultimate design of targeted, clinically
relevant options for treatment of human cutaneous SCCs.
Indeed, the emerging appreciation that cooperative EGFR
signaling is an essential aspect of TGF-b1-stimulated PAI-1
expression provides, to our knowledge, previously unre-
ported insights as to the effect of TGF-b1 in late-stage human
tumor progression, and underscores the potential diversity of
new molecular targets that can be exploited for therapeutic
benefit. Refining this understanding of PAI-1 gene regulation,
as well as its signaling pathways, may lead to the design of
transcription-focused ‘‘therapeutics’’ to manage human
cutaneous malignancies.
MATERIALS AND METHODS
Cell culture and immunocytochemistry
Subconfluent cultures of human HaCaT II-4 keratinocytes were
washed twice with phosphate-buffered saline (PBS) and maintained
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in serum-free DMEM for 1–3 days before stimulation with TGF-b1
(1 ngml–1) and/or EGF (10 ngml). EGFR/ and EGFRþ /þ mouse
embryonic fibroblasts were provided by Dr Jennifer R. Grandis
(University of Pittsburgh Medical Center). For immunocytochemis-
try, keratinocytes were fixed in paraformaldehyde (3.2%), permea-
bilized in 0.5% Triton X-100/PBS for 10minutes, blocked in 5% goat
serum/0.3% Triton X-100/PBS, and incubated with antibodies
to E-cadherin, N-cadherin (BD Transduction Laboratories,
San Jose, CA; 610182 and 610921, respectively), a-smooth muscle
actin (Sigma, St Louis, MO; a5228), vimentin (Abcam, Cambridge,
MA; ab45939), cyclin A, Ki-67 (both from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), pEGFRY845 (Cell Signaling, Danvers, MA;
2231), or PAI-1 (Wilkins-Port et al., 2009) for 1 hour at room
temperature. After three washes with 0.3% Triton X-100/PBS, cells
were incubated with appropriate secondary antibodies for 1 hour,
followed by a final series of 0.3% Triton X-100/PBS washes and
coverslips mounted with ProLong Gold antifade reagent (Invitrogen,
Carlsbad, CA) with 4,6-diamidino-2-phenylindole. Texas red–X
phalloidin was used to visualize actin microfilament structures.
Paraformaldehyde-fixed cells were stained with 0.5% crystal violet/
20% methanol/PBS for morphologic assessments. The pharmacolo-
gic agents U0126, PD169316, and SB220025 (10 mM final concen-
trations) were added 30minutes before stimulation; cells were
incubated with AG1478 (2.5 mM final concentration) for 45minutes
before growth factor addition. For inhibition of PAI-1 by function-
blocking (neutralizing) antibodies, cells were seeded at a low density
to form widely spaced individual colonies, serum starved, and PAI-1
polyclonal antiserum or preimmune serum (1% final concentration)
added simultaneously with TGF-b1þ EGF; 24–48 hours later, the
number of scattered colonies were counted. Colony dispersal was
quantified by the NIH ImageJ (http://rsb.info.nih.gov/ij/) analysis of
crystal violet-stained cultures at T0 and after TGF-b1þ EGF stimula-
tion. Careful seeding of single cells at low population densities
resulted in formation of rather uniform-sized colonies of closely
juxtaposed cells that approximated an area of 3–6 104 pixels.
‘‘Scattered’’ colonies, in contrast, had several distinguishing
characteristics, including loss of cell–cell contact, mesenchymal or
migratory phenotype, and area occupancy of 15–20 104 pixels.
PAI-1 siRNA constructs were from Dharmacon (Lafayette, Co). The
SMARTpool A-019376-13 to 16 SERPINE1 target sequences were
as follows: 50-CCGACAUGUUCAGACAGUU-30, 50-CCAAUGU
GUUCAAUAGAUU-30, 50-GGGGUGUACCUAAAUAUUU-30, and
50-GGGUUAUUUUGGAGUGUAG-30.
Western blotting
For detection of EGFR, pEGFRY845, pERK1/2, p38, phospho-p38, or
pHSP27, HaCaT II-4 cells were washed with cold PBS and scrape-
harvested on ice in cold lysis buffer (50mM HEPES, pH 7.5, 0.5%
deoxycholate, 1% Triton X-100, 1% NP-40, 150mM NaCl, 50mM
NaF, 1mM sodium orthovanadate, 2% protease inhibitor cocktail,
1mM p-nitrophenyl phosphate, 20 nM calyculin A, and 50 nM
okadaic acid). For the assessment of cellular PAI-1 protein levels,
cells were washed with PBS, trypsin-detached and collected by
centrifugation before lysis with RIPA buffer (50mM Tris pH 8.0,
150mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40,
and 1% protease inhibitor cocktail). Mouse embryonic fibroblasts
were disrupted in 4% SDS/PBS for 10minutes, and lysates vortexed
briefly, and boiled for 5minutes. All extracts were clarified by
centrifugation and 10–30 mg of protein was separated on denaturing
Tris-HCl SDS/10% PAGE gels. Upon nitrocellulose transfer,
membranes were blocked in 5% milk/0.05% Triton X-100/PBS for
1 hour, incubated with indicated antibodies, washed three times (in
0.05% Triton X-100/PBS) for 10minutes each, and incubated
with horseradish peroxidase-conjugated secondary antibodies. After
three 10-minute rinses, blots were incubated with enhanced
chemiluminescent substrate and exposed to X-ray film before
stripping for reprobing with ERK2 antibodies to assess overall
protein loading.
Transcriptional profiling
qRT-PCR analysis used the RT2 Profiler Cancer Pathway Finder qPCR
Array System (SABiosciences, Frederick, MD). RNA was isolated
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Figure 7. The EGFR is phosphorylated at Y845 in response to TGF-b1 and
required for plasminogen activator inhibitor-1 (PAI-1) induction.
(a) Stimulation of quiescent HaCaT II-4 cells with transforming growth factor-
b1 (TGF-b1) resulted in phosphorylation of the EGFR on the Y845 src kinase
target residue, although the kinetics of phosphorylation was delayed relative
to EGF-treated cultures. (b) While the level of phosphorylation was also
reduced compared with EGF-stimulated keratinocytes, suggesting perhaps the
involvement of a subset of receptors (a), both EGF- and TGF-b1-treated HacaT
II-4 cells effectively internalized the activated EGFR (b). To assess the
requirement for EGFR receptor presence for TGF-b1-induced PAI-1
expression, EGFR/ mouse embryonic fibroblasts (MEFs) were infected with
adenoviruses bearing either control (GFP) or wild-type human EGFR
expression constructs. EGFR/ MEFs or cells engineered to re-express a
wild-type EGFR (EGFRþ /þ ) were maintained in growth factor-free medium
(TGF-b1) or stimulated with TGF-b1 (þ TGF-b1; 1 ngml–1) for 5 hours.
(c) Western blots of PAI-1 levels in cellular extracts were quantified by
densitometry; data are the mean ±SD of triplicate independent experiments
normalized to total extracellular signal-regulated kinase 2 (ERK2) levels.
Scale bar in b¼ 10mm.
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using the RT2 qPCR-Grade RNA Isolation Kit and complementary
DNA was prepared from 0.5mg RNA samples using RT2 PCR Array
First Strand Kit. Real-time PCR used the Bio-Rad MyiQ Detection
System (Hercules, CA) with the following two-step cycling program:
a 10-minute incubation at 95 1C to activate the DNA polymerase,
followed by 40 cycles of 15 seconds at 95 1C and 1minute at 60 1C.
SYBR Green fluorescence was recorded for every well during the
annealing step of each cycle, and fold changes in gene expression
were calculated based on the threshold cycle (Ct) values. Relative
quantification for each gene in the array was normalized to that of
the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) using the SABiosciences integrated web-based software
to perform all DDCt-based fold-change qPCR data calculations.
EGFR ‘‘rescue’’ and knockdown
EGFR/ mouse embryonic fibroblasts were infected (multiplicity of
infection ¼ 50–100) with adenoviruses bearing either control (GFP)
or wild-type human EGFR1 expression constructs (gift of Dr Paula
McKeown-longo, Albany Medical College) in low-serum-containing
medium. Stimulation with TGF-b1 (1 ngml–1) was for 4 hours before
cell extraction. Adenovirus infectivity was 490% (assessed by
GFP fluorescence). HaCaT II-4 cells were similarly infected with
EGFR short hairpin RNA-bearing lentiviruses (Sigma) using the
TRCN000012120 2-6 clone set.
Oris cell invasion assay
Assessments of the ability of HaCaT II-4 keratinocytes to invade
through a three-dimensional extracellular matrix barrier were carried
out essentially as described (Platypus Technologies Oris Cell
Invasion Assay, Madison, WI) (Soltaninassab et al., 2008; Vasilaki
et al., 2010). A 96-well plate was coated with Oris basement
membrane extract, allowed to dry, and a polymeric insert was fitted
to the inside of the wells to prevent cells from entering the inner
analytic zone before seeding 1 105 HaCaT II-4 cells per well. After
the cells became confluent (2 days), they were serum-deprived
(1 day) and the stopper inserts were removed creating a vacant
invasion zone in the center of the well. The cells were overlaid with
basement membrane extract to form a three-dimensional matrix
barrier. Although cells may continue to proliferate in the peripheral
regions of the well under the basement membrane extract overlay,
proteolytic activity is required to invade the barrier and enter the
analytic area (Soltaninassab et al., 2008). TGF-b1 and/or EGF with or
without inhibitors were added to serum-free DMEM after serum
starvation and incubated for 72–96 hours before fixation with 3.2%
paraformaldehyde and 4,6-diamidino-2-phenylindole staining. Re-
combinant PAI-1, when used, was added exogenously as described
(Providence et al., 2008). An optical mask was applied to the plate
bottom to block from view all cells except those that had invaded
into the center analytic zone before photography. For siRNA
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treatment, cells were transfected, trypsinized, and seeded as
described above.
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